In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Improvements were also seen in complete response rates, duration of response, and time to next treatment
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
Subscribe To Our Newsletter & Stay Updated
